Johnson & Johnson

Johnson & Johnson declined 1.62% intraday to $266.17, reflecting the impact of a severe third-quarter earnings miss and profit-taking following a substantial prior rally. Q3 results revealed a troubling deterioration: earnings per share plummeted 95.89% year-over-year to just $0.0872, while net profit crashed 95.92% to $210 million and net margin collapsed from 21.86% in Q2 to just 0.83%, despite revenue growing 5.86% to $25.4 billion. On a brighter note, the medical technology segment reported positive clinical data with Impella heart pumps demonstrating a 94% success rate in coronary artery intervention trials. The stock currently trades 5.62% below its 52-week high of $282.01 reached on October 30, yet remains up 28.37% year-to-date from $207.35 and continues to trade above both its 20-day and 60-day moving averages. Nevertheless, a P/E ratio of 39.81 reflects stretched valuation that may constrain further upside momentum.

Johnson & Johnson rose 3.8% to close at $267.61 today, driven primarily by recent product pipeline advances. Key catalysts include VARIPULSE Pro achieving 100% acute procedural success in atrial fibrillation trials, TALVEY plus daratumumab securing CHMP endorsement for expanded myeloma indication, and the launch of next-generation Shockwave™ C2 Aero Fly coronary IVL catheter, which cuts treatment time by 50%. Positionally, JNJ is up nearly 29% year-to-date and sits just 4.8% below its 52-week high of $281.07, near yearly peaks. However, Q3 earnings revealed a concerning 96% plunge in net profit and EPS despite 5.86% revenue growth year-over-year, and the current 40x P/E valuation sits at historically elevated levels, with profit-taking pressure evident after the substantial rally.

Johnson & Johnson closed at $258.28, down 0.37% from the prior session, primarily reflecting the shock of a dramatic earnings miss in Q3. Third-quarter EPS plummeted to merely $0.0858, a 95.95% decline year-over-year, with net profit collapsing to just $210 million (down 95.92%), despite revenues maintaining growth at $25.4 billion (up 5.86% YoY). On the product front, recent progress includes the launch of next-generation Shockwave C2 Aero coronary IVL catheter, Tremfya's demonstrated efficacy in Crohn's disease fistula remission, and TALVEY's approval for earlier-stage multiple myeloma—underpinning innovation momentum. Year-to-date gains stand at 24.32%, with the stock now 8.29% below the 52-week high of $281.07, while trading at a relatively lofty P/E of 38.6x. Analysts maintain a $300 price target, though divergent views persist regarding profit recovery risks in the near term.

Johnson & Johnson rose 2.2% to $259.36 in intraday trading with strength reaching $260.77, driven by a broader healthcare sector rally and falling oil prices, supported by positive product catalysts including the next-generation Shockwave™ C2 coronary intervention catheter cutting treatment time in half and Tremfya data showing durable fistula remission through 48 weeks in Crohn's disease. The company reiterated its raised sales outlook, backing analyst buy ratings with a $300 price target. However, Q3 earnings paint a concerning picture: while operating revenue grew 5.86% to $25.4 billion, net profit plummeted 95.92% to just $210 million and EPS fell to $0.0858, revealing severe margin compression beneath revenue growth. On price positioning, the stock is up 25.08% year-to-date but trades 7.72% below the 52-week high of $281.07 and sits below the 60-day moving average, with an elevated PE ratio of 38.83 amid these earnings headwinds.

Johnson & Johnson rose 0.90% to $255.56 today, rebounding after Q3 earnings disappointment. The company posted Q3 EPS of $0.0858, down 95.95% year-over-year, with net profit collapsing to $210 million, a 95.92% decline. Net margin plunged from 21.86% in Q2 to just 0.83%, prompting analysts to cut forecasts broadly. This earnings deterioration drove an approximate 5% stock decline in recent sessions. However, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recently recommended approval of J&J's TALVEY combination therapy for earlier-line treatment of relapsed/refractory multiple myeloma, providing oncology growth catalysts. The company is also pursuing strategic acquisitions to counter market headwinds. Trading 23.25% above its 2026 starting price of $207.35, J&J trades 9.08% below its 52-week high of $281.07 but 38.39% above the 52-week low of $184.66. Notably, the company faces pending legal investigation notices from entities including SueWallSt.